drugset

drugset / Trial / NCT04893161

A Model About the Response of Belimumab in SLE

NCT04893161 ↗

Phase 4 Unknown 72 enrolled First Affiliated Hospital Xi'an Jiaotong University

NaSingle-groupOpen-labelTreatment

Summary

A prospective, single-center cohort study aims to determine a predictive model of the response of belimumab at Week 48.

Timeline

Start: 2024-06-01
Primary completion: 2026-01-31
Completion: 2026-01-31

Publications

Wang J, Ju B, Zhu L, Li H, Luo J, Zhang J, Hu N, Mo L, Wang Y, Pan Y, Huang J, Lv X, Pu D, Hao Z, He L, Li Y. The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients. Front Pharmacol. 2023 Feb 16;14:1080730. doi: 10.3389/fphar.2023.1080730. eCollection 2023.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belimumab	Monoclonal antibody	10 mg/kg	Intravenous

Indications